Ceplene but competition that will be rolled out to all the world markets, Meda currently sells in 120 countries and the agreement will be supplemented. Studies for more indications will start soon. Phase III directly.
Neither seems to understand that so many Ceplene is quite vital, that is pretty easy to sell and achieve forecast sales targets.
Yet analysts insist on eg va and exchange week to count only the EU, and about 10% royalty, and also hesitant about the sale.
facts of the matter is that average for the market approved orphan drugs is 25% royalty and upwards!
It is almost certainly that the Company will be there for the EU. but at least 10-15% outside the EU.
U.S. takes EpiCept completely themselves, leaving a huge Avans, certainly between 80-85%. EpiCept will quickly come up in the net income of only matched by blockbuster sales with a low royalty.
Still have not Ceplene a chance if we are to compare with EpiCept's real blockbuster NP-1.
So where are the market actors house? awaiting an offer of 150-200% so they do not have to worry then. Missed the case, thank you and goodbye! "